Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 13;21:719. doi: 10.1186/s12967-023-04585-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — A (a) Cytoplasmic vimentin expression levels in Hct116 PDCs before and after mutation of the SUMO site (K373/K439/K445, K373/K439, K439/K445, and K373/K445). b Cytoplasmic vimentin expression levels in LoVo PDCs before and after mutation of the SUMO site (K373/K439/K445, K373/K439, K439/K445, and K373/K445). B (a) Nuclear vimentin expression levels in Hct116 PDCs before and after mutations at the SUMO site (K373/K439/K445, K373/K439, K439/K445, and K373/K445); b nuclear vimentin expression levels in LoVo PDCs before and after mutations at the SUMO site (K373/K439/K445, K373/K439, K439/K445, and K373/K445). C Western blot analysis of P62 protein levels. a Total protein level of P62, b cytoplasmic level of P62, and c nuclear level of P62. D (a) Results of vimentin coimmunoprecipitation in Hct116 control cells and Hct116 PDCs (anti-vimentin antibody was used for immunoprecipitation). b Results of vimentin coimmunoprecipitation in LoVo control cells and LoVo PDCs (anti-vimentin antibody was used for immunoprecipitation). E (a) Total P62 expression levels in Hct116 PDCs after siRNA-P62 (358, 473, 531) transfection. b Total P62 expression levels in LoVo PDCs after siRNA-P62 (358, 473, 531) transfection. F (a) Total vimentin, SUMO1, and SUMO2/3 expression levels after siRNA-P62. b Cytoplasmic vimentin, SUMO1, and SUMO2/3 expression levels after siRNA-P62. c Nuclear vimentin, SUMO1, and SUMO2/3 expression levels after siRNA-P62. SUMO small ubiquitin-like modification, PDCs polyploid giant cancer cells with daughter cells